AI Article Synopsis
- Anti-NMDAR encephalitis is a serious autoimmune brain condition that can affect anyone, but is more common in kids, and unfolds in five stages: prodromal, psychotic, unresponsive, hyperkinetic, and recovery.
- Treatment involves first-line options like steroids and intravenous immunoglobulin, along with second-line therapies such as rituximab and tumor removal.
- The text discusses the advancements, choices, and limitations of these treatment approaches for the condition.
Article Abstract
Anti-N-methyl-D-aspartate receptor (anti-NMDAR) encephalitis is a new category of severe, potentially treatable autoimmune encephalitis and can appear in patients of all ages, but more frequently in children. It is a highly characteristic syndrome evolving in five stages: the prodromal phase (viral infection-like symptoms), psychotic phase, unresponsive phase, hyperkinetic phase, and gradual recovery phase. The treatment for this disorder includes first-line immunotherapy (steroids, intravenous immunoglobulin, plasmapheresis), second-line immunotherapy (rituximab, cyclophosphamide), and tumor removal. Hereby the progresses, selections and shortcomings of the treatment protocols for this disease are introduced.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!